SNCE Key Statistics, Chart & Performance
The current stock price of SNCE is 5.75 USD. In the past month the price increased by 1.23%. In the past year, price decreased by -19.47%.
SNCE Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to SNCE. When comparing the yearly performance of all stocks, SNCE is a bad performer in the overall market: 70.82% of all stocks are doing better.
SNCE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SNCE. The financial health of SNCE is average, but there are quite some concerns on its profitability.
SNCE Financial Highlights
Over the last trailing twelve months SNCE reported a non-GAAP Earnings per Share(EPS) of -7.26. The EPS decreased by -881.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -164.66% | ||
| ROE | -241.1% | ||
| Debt/Equity | 0 |
SNCE Forecast & Estimates
10 analysts have analysed SNCE and the average price target is 14.11 USD. This implies a price increase of 145.39% is expected in the next year compared to the current price of 5.75.
For the next year, analysts expect an EPS growth of -72.66% and a revenue growth -14.69% for SNCE
SNCE Ownership
SNCE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 28.08 | 236.36B | ||
| DHR | DANAHER CORP | 30.84 | 167.96B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 192.99 | 58.64B | ||
| IQV | IQVIA HOLDINGS INC | 20.5 | 40.61B | ||
| A | AGILENT TECHNOLOGIES INC | 24.74 | 39.13B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 34.09 | 29.14B | ||
| WAT | WATERS CORP | 30.49 | 23.05B | ||
| ILMN | ILLUMINA INC | 34.47 | 22.96B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 35.26 | 17.93B | ||
| MEDP | MEDPACE HOLDINGS INC | 42.52 | 17.13B | ||
| RVTY | REVVITY INC | 23.65 | 12.85B | ||
| TEM | TEMPUS AI INC | N/A | 11.35B |
Related stock screener links
About SNCE
Company Profile
Science 37 Holdings Inc is a US-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Research Triangle Park, North Carolina and currently employs 460 full-time employees. The company went IPO on 2020-11-20. Science 37 Holdings, Inc. is engaged in patient-centric clinical trials and in supporting novel approaches to decentralized clinical trial designs. Through its patient-centric approach, it reduces the impact of the geographic barriers associated with conventional physical clinical trial sites, enabling recruitment of virtually any patient. Its offerings lie in its configurable unified technology platform combined with its centralized patient recruitment capabilities and specialized network of patient communities. Its unified technology platform is purpose-built for patient-centric clinical trial execution and is designed to provide an end-to-end, single stop solution. The company also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, and remote coordinators designed for the purpose of orchestrating patient-centric clinical trials. The company uses diversified, multi-channel programs to identify patients who fit the profile for each of its projects.
Company Info
SCIENCE 37 HOLDINGS INC
800 Park Offices Drive, Suite 3606
RESEARCH TRIANGLE PARK NORTH CAROLINA US
CEO: Andrew McDonald
Employees: 460
Phone: 19843773737
SCIENCE 37 HOLDINGS INC / SNCE FAQ
What does SNCE do?
Science 37 Holdings Inc is a US-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Research Triangle Park, North Carolina and currently employs 460 full-time employees. The company went IPO on 2020-11-20. Science 37 Holdings, Inc. is engaged in patient-centric clinical trials and in supporting novel approaches to decentralized clinical trial designs. Through its patient-centric approach, it reduces the impact of the geographic barriers associated with conventional physical clinical trial sites, enabling recruitment of virtually any patient. Its offerings lie in its configurable unified technology platform combined with its centralized patient recruitment capabilities and specialized network of patient communities. Its unified technology platform is purpose-built for patient-centric clinical trial execution and is designed to provide an end-to-end, single stop solution. The company also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, and remote coordinators designed for the purpose of orchestrating patient-centric clinical trials. The company uses diversified, multi-channel programs to identify patients who fit the profile for each of its projects.
Can you provide the latest stock price for SCIENCE 37 HOLDINGS INC?
The current stock price of SNCE is 5.75 USD. The price increased by 0.35% in the last trading session.
What is the dividend status of SCIENCE 37 HOLDINGS INC?
SNCE does not pay a dividend.
What is the ChartMill technical and fundamental rating of SNCE stock?
SNCE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for SNCE stock?
10 analysts have analysed SNCE and the average price target is 14.11 USD. This implies a price increase of 145.39% is expected in the next year compared to the current price of 5.75.
What is the market capitalization of SNCE stock?
SCIENCE 37 HOLDINGS INC (SNCE) has a market capitalization of 34.67M USD. This makes SNCE a Nano Cap stock.